● Black Diamond Therapeutics is a Cambridge, Massachusetts-based precision-oncology company.
ACybersecuritybreach has forced one of the largest names in medical devices to warn that it will miss its own financial targets. Boston Scientific Corporation (NYSE: BSX) disclosed that unauthorized network activity disruptedManufacturingand shipping across its global operations, and that the fallout will materially dent …
Affimed N.V. (OTC:AFMDQ) is a cautionary chapter in immuno-oncology. Once a Nasdaq-listed developer of innate-immunity cancer therapies with a well-followed pipeline, the company's shares have collapsed to a fraction of a cent and now change hands over the counter under a ticker carrying the …
AlumiFuel Power Corporation (OTC:AFPW) belongs to a quiet corner of the market where once-promising clean-energy stories went dark. The company built its pitch around hydrogen, generating gas and heat by reacting aluminum with water, but its most recent verifiable milestones date back roughly half …
Amarantus BioScience Holdings, Inc (OTC:AMBS) has spent years chasing ambitious ideas across neurology, diagnostics and regenerative medicine, yet its stock tells a starker story. AMBS now changes hands at a fraction of a cent, with aMarket Valuemeasured in the hundreds of dollars and no …
● For a profitable, cash-generating pharmaceutical company, share performance tends to track fundamentals and sector sentiment rather than binary news.
Anthera Pharmaceuticals (OTC:ANTH) belongs to a large graveyard of clinical-stage biotechs whose lead programs failed and whose shares dwindled to almost nothing. Once a Nasdaq-listed developer of treatments for autoimmune and rare diseases, Anthera has left virtually no fresh public footprint for years.
Aridis Pharmaceuticals (OTC:ARDS) was once a Nasdaq-listed developer of antibody therapies for serious infectious diseases, but the stock now trades for a fraction of a cent on the over-the-counter market in the last closing session. The company's public disclosure has thinned dramatically, and its …
Athersys, Inc (OTC:ATHXQ) spent the better part of two decades pursuing an ambitious idea: an off-the-shelf regenerative cell therapy, MultiStem, that could treat conditions ranging from stroke to acute respiratory distress. The science drew genuine interest, but theBusinesscould not outrun its cash needs, and …
● Interest reflects improving fundamentals and a supportive analyst view rather than a confirmed single-day catalyst.